<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456248</url>
  </required_header>
  <id_info>
    <org_study_id>VRX-CIFN-402</org_study_id>
    <nct_id>NCT00456248</nct_id>
  </id_info>
  <brief_title>Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin</brief_title>
  <acronym>ENHANCE</acronym>
  <official_title>Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 60-to-72 week multicenter study to evaluate Infergen and Ribavirin in patients with
      Chronic Hepatitis C Virus after partial response to treatment using peginterferon-alfa and
      Ribavirin therapy. The study will be conducted at approximately 50 sites across the United
      States.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow enrollment
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the proportion of patients with a sustained viral response (SVR) defined as undetectable serum HCV RNA at the end of the 24 week post-treatment follow-up period.</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare proportion of patients with SVR after switching treatment with Infergen/Ribavirin for 48 weeks versus those treated for 36 weeks</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infergen 15 ug QD plus RBV for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infergen 15 ug QD plus RBV for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infergen and ribavirin</intervention_name>
    <description>Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, at least 18 years of age and no older than 65 years with compensated
             chronic HCV infection based on a history of positive serum anti-HCV antibody and/or
             HCV RNA

          -  Diagnosed with HCV Genotype 1, 4, 5 or 6 as determined during the screening visit

          -  The starting doses in the initial treatment must have been 1.5 μg/kg/week PEG-Intron
             or 180 μg/week Pegasys, and 1000/1200 mg/day ribavirin based on body weight. Patients
             must have been at least 80% compliant during the initial peginterferon/ribavirin
             therapy, per patient account.

          -  Liver biopsy indicating F0-F4 must be performed within 3 years prior to screening.
             Documentation of the results of the biopsy must be available. If documentation is not
             available, a liver biopsy must be performed during the screening period. (A maximum of
             10 patients in each of the three treatment groups will be patients with a fibrosis
             score of F4)

          -  Documented partial response after 12 weeks of treatment as a therapy-naive patient
             with one course of peginterferon alfa-2a (PEGASYS) and Ribavirin or peginterferon
             alfa-2b (Peg-INTRON) and Ribavirin

        Exclusion Criteria:

          -  Detectable HCV RNA after 12 weeks if initial peginterferon alfa/ribavirin therapy and
             &lt;2 log decrease in HCV RNA at Week 12 from baseline.

          -  HCV Genotype 2 or 3

          -  Severe neuropsychiatric disorder.

          -  History or clinical manifestations of significant metabolic, hematological, pulmonary,
             ischemic heart disease, significant or unstable heart disease, gastrointestinal,
             neurological, renal, urological, endocrine, ophthalmologic disorders including severe
             retinopathy, or immune-mediated disease.

          -  Known HIV infection or positive HIV at screening.

          -  Pregnant or breast-feeding patients.

          -  Underlying autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell L Schiffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlantic Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caroline Digestive Health Associates</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute at Methodist Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>October 11, 2012</last_update_submitted>
  <last_update_submitted_qc>October 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Liver</keyword>
  <keyword>Pegylated</keyword>
  <keyword>Interferon</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Combination</keyword>
  <keyword>Nonresponder</keyword>
  <keyword>Relapser</keyword>
  <keyword>HCV</keyword>
  <keyword>Infergen</keyword>
  <keyword>SVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon alfacon-1</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

